StockData
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31

Trevi Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.90+0.02 (+0.17%)

Close on Oct 19, 2026

Market cap
$1.86B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 12, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026During market hours–$-0.11–
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026During market hours–$-0.09–
Q4 FY2025
Ended Dec 31, 2025
Mar 17, 2026During market hours–$-0.06–
Q3 FY2025
Ended Sep 30, 2025
Nov 13, 2025During market hours–$-0.08–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours–––
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025During market hours–––
Q4 FY2024
Ended Dec 31, 2024
Mar 18, 2025During market hours–$-0.11–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours–$-0.13–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024During market hours–$-0.12–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024During market hours–$-0.11–
Q4 FY2023
Ended Dec 31, 2023
Mar 20, 2024During market hours–$-0.08–

Press releases

Announcements Trevi Therapeutics filed with the SEC